Form 4: Ionis Pharma EVP Granted 9,100 Stock Options

Ionis Pharmaceuticals' EVP, Chief Development Officer Holly B. Kordasiewicz, was granted 9,100 non-qualified stock options with a $79.67 exercise price.

Summary

• Holly B. Kordasiewicz, Executive Vice President and Chief Development Officer of IONIS PHARMACEUTICALS INC (IONS), was granted 9,100 non-qualified stock options.
• The transaction date for this grant was January 2, 2026.
• The exercise price for these stock options is $79.67 per share.
• The options were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• Vesting for these options will occur in stages: 25% of the shares will vest on January 2, 2027, and the remaining shares will vest in 36 equal monthly installments over the subsequent three years.
• The expiration date for these stock options is January 1, 2036.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns executive interests with shareholder value, which is generally viewed favorably as an incentive for long-term performance. It is a routine disclosure without immediate negative implications.

Positives

• The grant of stock options to a key executive aligns management's long-term interests with those of shareholders, incentivizing performance and value creation.
• This is a standard form of executive compensation, indicating continued commitment to retaining and motivating senior leadership.

Risks

• The value of the stock options is subject to the future market price fluctuations of IONIS PHARMACEUTICALS INC common stock.
• If the company's stock price does not exceed the exercise price of $79.67, the options may not hold significant intrinsic value.
• Future exercises of these options could lead to a minor dilutive effect on existing shares, although this is typical for equity compensation plans.

Future Outlook

The vesting schedule for the granted stock options extends over several years, indicating a long-term incentive structure designed to align the executive's performance with the company's sustained growth and shareholder value creation.

Industry Context

Equity compensation, particularly through stock options, is a prevalent practice in the biotechnology and pharmaceutical industries. It serves as a critical tool to attract, retain, and motivate highly skilled executives by linking their personal financial success to the long-term performance of the company, which is essential in a sector characterized by lengthy development cycles and significant R&D investments.

Comparison to Industry Standards

• The grant of stock options to a Chief Development Officer is a standard component of executive compensation packages across publicly traded companies, especially within the biotech sector.
• The vesting schedule, with an initial cliff and subsequent monthly installments over three years, is a common structure designed to encourage long-term commitment and performance, comparable to practices at companies like Amgen, Gilead Sciences, or Biogen.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aims to align the interests of a key executive with shareholders, potentially leading to enhanced long-term company performance and value creation.
• Employees: This grant is part of the company's broader compensation strategy, which can influence morale and retention of other employees, particularly those in leadership roles.

Next Steps

• The stock options will begin to vest on January 2, 2027, with subsequent monthly vesting over the following three years.
• The reporting person may choose to exercise vested options at any time before the expiration date of January 1, 2036, subject to company policy and blackout periods.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Stock Options, Executive Compensation, Form 4, Insider Transaction, Equity Incentive Plan, Biotechnology, Pharmaceuticals